GxP regulations are in place to ensure the purity, quality, and safety of pharmaceuticals. Manufacturing and quality control
testing of approved drugs falls under good manufacturing practice (GMP) regulations. Safety studies for drugs are regulated
by good laboratory practice (GLP) regulations. There currently are no guidelines for drug discovery and biomedical research
activities. This phase of drug development is relevant to stage 1 product design in the pharmaceutical product lifecycle.
Because researchers have no standard to follow, there is often wasted time and effort when unreliable studies need to be repeated.
A working group from the American Society for Quality (ASQ) Food, Drug, and Cosmetics Division (FD&C) published its first
technical report, Best Quality Practices for Biomedical Research in Drug Development, in June 2012. This report addresses the need for biomedical research standards and provides the first step leading to the
eventual creation of an ISO standard. Drugs and therapeutic products touch our daily lives in myriad ways. From the vitamins
and aspirin we take for common ailments to the cardiac and cancer treatment medicines for serious illness to the hormones
in animal feeds, these drug products find their way into everyday use. The public's interest is captured by the expectations
provided by biomedical research and drug development. Besides the commercial value, the governmental and private funding support
in the developed countries, primarily the US, provides the overarching hope of curing human illness and suffering, while providing
the additional benefit of greater economic development. One aspect all drug developments have in common is specific government
regulations known as GMPs. These regulations ensure that drug products are safe, pure, and efficacious. The GMP regulations
ensure that all aspects of the manufacturing processes use "good practices" and science to produce drugs with the integrity
and validity the process was intended to produce. These regulations can all be found under their respective sections of the
Code of Federal Regulations (CFR) Title 21, Parts 210 and 211 in the US. Similar documents exist in Canada, Europe, and globally through the World Health
Routine medical laboratories involved in patient care are covered by well-defined international quality standards (ISO 15189)
and national laws (42 CFR 493). In pharmaceutical R&D, only the nonclinical laboratory safety studies are governed by the GLP regulations 21 CFR Part 58. There are no other well-defined quality standards existing for other non-GLP laboratory research, including biomedical
research that may lead to new drug discovery. This potentially causes an incongruous situation in a biomedical research laboratory,
where for example, a blood sample from a rabbit is subjected to stricter quality standards than a human sample. FDA expects
that "sound quality principles" are applied to the processing of human samples, but these principles are not well defined
Much of the aforementioned investment, both financial and research, comes from the US. For example, the proportion of the
global drug-development pipeline belonging to organizations headquartered in the United States has increased to 80% in the
past decade (1). In the US alone, about $68 billion per year is spent on biomedical research. Due to poorly designed studies
or the irreproducibility of biomedical research data and studies, the consequences of pursuing a drug development dead end
have become an increasingly serious issue. The credibility of this biomedical research data has lead to costly and often futile
attempts at repetition of these studies. These efforts are a unnecessary waste of scarce valuable funding resources. Is it
not better that the spending on these drug-development programs find new therapeutics for the many unmet medical needs and
not be squandered on irreproducible or worse, fraudulently reported research?
The National Center for Dissemination of Disability Research published a whitepaper that supports this concept... "the
widespread belief that the quality of scientific research is often uneven and lacking in credibility, making it difficult
to make a confident, concrete assertion or prediction regarding evidence for improving practice or consumer outcomes (Levin
& O'Donnell, 1999; Mosteller & Boruch, 2002; Shavelson & Towne, 2002). ...is also due, in part, to the lack of consensus on
the specific standards for assessing quality research and standards of quality for assessing evidence (Gersten et al., 2000;
Mosteller & Boruch, 2002). For example, several researchers have contended that some of the current peer review processes
and standards for assessing quality are not well suited for research in the disability arena (Gersten et al., 2000; NCDDR,
2003; Spooner & Browder, 2003)" (2).
There has been an overall significant decline of productivity in pharmaceutical biomedical research over the past 15 years
when comparing the number of new medicines to the equivalent funding spent in R&D (see Figure 1).
Figure 1: New Molecular Entities (NME) and R&D spending 2001-2009.
Obstructions to new drug entity breakthroughs have received much scrutiny since the recent decade-long decline in new drug
approvals. Thus, notwithstanding the doubling of biomedical research funding and the shift toward clinical research by pharmaceutical
companies, "the number of new molecular entities approved by FDA has fallen...as a consequence, pharmaceutical productivity
decreased over the last 10 years, and it is lagging behind that of the biotechnology and device sectors... Financial return
to investors has paralleled those changes in productivity" (3).
One of the root causes for the reproducibility problem is the lack of a common quality standard for nonregulated biomedical
research. Traditionally, non-regulated biomedical research has been considered off-limits for formal quality standards. Scientists
in general regard their work as a highly intellectual activity where quality is knowledge and experience is an integral part
of the scientific rigor that they apply. A longstanding tradition of quality control in science has been peer review of the
results, but modern pharmaceutical research has become so complex that peer review has a limited value today. Also, "some
scholars suggest that while standards such as peer review and standardized reporting are important benchmarks, research should
not be judged solely by whether or not it is published in the leading journals (Boaz & Ashby, 2003). While journal publication
and citation analysis provide quantitative data, it is a faulty assumption that all 'research' that is published in journals
or cited by others is accurate, reliable, valid, free of bias, non-fraudulent, or of sufficient quality (Boaz & Ashby, 2003).
Further, citation analysis is primarily a measure of quantity and can be artificially influenced by journals with high acceptance
rates (COSEPUP, 1999)" (4).
The scope and dimension of modern research is moving science out of the realm of individual scientists and into a globalized
team where standards, transparency, and reproducibility have become key requirements. Scientific work that cannot be reproduced
or independently verified by others is a waste of valuable limited resources. Also, biomedical research generates intellectual
property, which has become increasingly subject to internal and external scrutiny and is often challenged in litigations.
The authenticity and integrity of scientific data underlying an intellectual property claim are therefore of utmost importance.
To prove the authenticity and integrity of scientific data, studies and experiments must be conducted under controlled and
A common quality guideline when utilized in biomedical research and drug development will ensure the validity and credibility
of scientific data from different research institutions and facilitate the mutual acceptance of research results. Such a document
will help to eliminate unnecessary duplication of existing research work, make published research data more reliable, and
increase the overall lagging productivity of biomedical research. These attributes will benefit patients worldwide by speeding
drugs to market, meet global regulatory compliance requirements, and enhancing investor interest in developing new innovative
drug product that produce a solid return on investment (5).